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Abstract
Background: Uptake of colorectal cancer screening is low in the English NHS Bowel Cancer Screening Programme
(BCSP). Participation in screening is strongly associated with socioeconomic status. The aim of this study was to determine
whether a supplementary leaflet providing the ‘gist’ of guaiac-based Faecal Occult Blood test (gFOBt) screening for
colorectal cancer could reduce the socioeconomic status (SES) gradient in uptake in the English NHS BCSP.
Methods: The trial was integrated within routine BCSP operations in November 2012. Using a cluster randomised
controlled design all adults aged 59–74 years who were being routinely invited to complete the gFOBt were randomised
based on day of invitation. The Index of Multiple Deprivation was used to create SES quintiles. The control group received
the standard information booklet (‘SI’). The intervention group received the SI booklet and the Gist leaflet (‘SI + Gist’)
which had been designed to help people with lower literacy engage with the invitation. Blinding of hubs was not
possible and invited subjects were not made aware of a comparator condition. The primary outcome was the gradient
in uptake across IMD quintiles.
Results: In November 2012, 163,525 individuals were allocated to either the ‘SI’ intervention (n = 79,104) or the
‘SI + Gist’ group (n = 84,421). Overall uptake was similar between the intervention and control groups (SI: 57.3% and
SI + Gist: 57.6%; OR = 1.02, 95% CI: 0.92–1.13, p = 0.77). Uptake was 42.0% (SI) vs. 43.0% (SI + Gist) in the most deprived
quintile and 65.6% vs. 65.8% in the least deprived quintile (interaction p = 0.48). The SES gradient in uptake was similar
between the study groups within age, gender, hub and screening round sub-groups.
Conclusions: Providing supplementary simplified information in addition to the standard information booklet did not
reduce the SES gradient in uptake in the NHS BCSP. The effectiveness of the Gist leaflet when used alone should be
explored in future research.
Trial registration: ISRCTN74121020, registered: 17/20/2012.
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Background
Biennial screening using guaiac-based Faecal Occult Blood
testing (gFOBT) reduces colorectal cancer (CRC) mortality
[1]. The National Health Service (NHS) Bowel Cancer
Screening Programme (BCSP) in England offers biennial
CRC screening by gFOBt to all adults aged 60–74 years.
Uptake from 2006 to 2009 was 54%, [2] which is lower than
the breast (73%) and cervical programmes (79%) [3, 4].
These data also demonstrate a strong gradient in uptake by
socioeconomic status (SES), with uptake ranging from 35%
in the most deprived area quintile to 61% in the least
deprived quintile [2]. Adherence to follow-up procedures is
high (88%) and shows little association with SES [5].
Low engagement with screening information may
partially explain disappointing uptake rates [6]. A large
proportion of people in deprived areas have low literacy
skills [7] and information materials may be too complex
to facilitate informed decision-making [8–11]. Difficulties
with comprehending the existing information booklet,
‘Bowel Cancer Screening: The Facts’ may explain why lim-
ited literacy is a risk factor for sub-optimal participation
[12–14]. Multiple socioeconomic factors affect screening
participation, however literacy has been shown to be an
independent predictor of uptake after adjusting for age,
sex, education, occupation, ethnicity and wealth [12].
Literacy-related barriers can be addressed face-to-face or
by telephone contact, [15] but this is not practical within a
national screening programme.
Psychological models argue that decision-making can be
improved for people with poor literacy by providing the
‘gist’ of information (e.g. ‘screening saves lives’) [16].
Highlighting the ‘gist’ of screening and removing unneces-
sary information could improve the ease with which
screening decisions can be reached, particularly for lower
socioeconomic status groups. We developed a gist-based
information leaflet that begins with statements encapsulat-
ing the main aims of CRC screening, followed by key
information in simple language [17]. In line with NHS
policy, the Gist leaflet was sent as a supplement to the
standard information booklet. We hypothesised that the
Gist leaflet would be progressively more effective in
improving screening uptake with increasing levels of area-
based socioeconomic deprivation.
Methods
The study was a two-arm, cluster-randomised trial with
individuals routinely invited for CRC screening within the
NHS BCSP. They received either: the standard informa-
tion booklet (SI); or, the standard booklet plus the supple-
mentary Gist leaflet (SI + Gist). The trial had multicentre
ethics approval from the National Research Ethics Service
Committee London-Harrow (REC ref.: 12/LO/1396). The
Cancer Screening Programmes are covered by National In-
formation Governance Board (NIGB) approval for handling
patient-identifiable data. The trial was prospectively regis-
tered on the 17th October, 2012 (ISRCTN74121020). We
adhered to the Consort guidelines throughout.
Setting and participants
The administration of the BCSP is co-ordinated by five
regional centres or ‘hubs’. Each hub sends an invitation
and the screening information every 2 years from the 60th
birthday to all patients registered with a General Practi-
tioner (GP) in their region. The gFOBt kit is sent 8–
10 days later, along with instructions on how to perform
the test. To participate in screening, the individual collects
small samples from three bowel motions, and returns the
kit to the hub in a pre-paid envelope. A reminder is sent
after 4 weeks to those who have not responded. If there
has not been a response to the invitation after 13 weeks,
the ‘screening episode’ is closed. The hubs process the kits
and the result is sent to the individual and their GP within
2 weeks. Routine gFOB testing is offered 2 years later for
those with a normal result. A repeat test is sent for a spoilt
kit, a technical fail, or an unclear result. Each hub works
with up to 18 local screening centres which are respon-
sible for providing follow-up investigations for individuals
with abnormal results.
This trial involved all five hubs and included all indi-
viduals invited during the study period. Individuals not
registered with a GP (~4% of the population) were not
included, and those who opted out of screening were
not sent further kits. People undergoing investigation for
colorectal problems or who had undergone bowel sur-
gery are requested to seek advice from a helpline.
Intervention
Control group: Standard Information booklet (SI).
Screening invitees were mailed the standard invitation 2
weeks before their screening kit. The invitation was sent
in an NHS envelope and contained an invitation letter
and ‘The Facts’ booklet. After 2 weeks, invitees were
mailed a gFOBt kit with a standard instructional leaflet.
Intervention group: Standard Information booklet + Gist
leaflet (SI + Gist). People in the intervention group
received the Gist leaflet 2 weeks before the screening kit
in the same envelope as the standard booklet. A copy of
the Gist leaflet can be found in Additional file 1: Fig. S1.
The Gist leaflet was developed using the General Med-
ical Council guidelines [18]. The development process is
described elsewhere [17, 19]. Structured interviews identi-
fied areas of the standard information booklet susceptible
to being misunderstood [20]. We addressed problematic
areas in the Gist leaflet by using principles of information
design [16]. The Gist leaflet underwent user-testing to
refine its readability and comprehensibility [17]. The
acceptability of the Gist leaflet and its effect on knowledge
was demonstrated in a randomised controlled trial
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(n = 964) with adults from deprived areas [19]. The organ-
isation and schedule of the trial is shown in Additional
file 2: Fig. S2.
Randomisation
Randomisation was by day of invitation, with ‘day within
Hub’ constituting the randomisation unit (hub-day).
Randomisation occurred over 10 consecutive days in
November 2012. Two weeks prior, the randomisation se-
quence was generated for each hub-day by the trial statis-
tician and sent to the organisations handling the mailing:
Real Digital International (RDI) for the Southern, London
and Eastern hubs, and an ‘in house’ system for the North-
East and North West Hubs. For each hub, ten random
numbers were generated. Hub-days above the median
random number were allocated to intervention and hub
days below to control. Blinding of hubs was not possible,
but bias was unlikely due to the lack of contact with sub-
jects [21]. Invited subjects were unaware of a comparator
condition unless a member of their household was also
invited during the study period.
Outcome measures
Screening uptake was defined as the return of a gFOBt
kit within 18 weeks of the invitation that led to a ‘defini-
tive’ test result of either ‘normal’ (i.e. no further investi-
gation required) or ‘abnormal’ (i.e. referral for further
testing, usually colonoscopy) by the date of data extrac-
tion (18 weeks after the last day of the intervention).
People were classified as not adequately screened if their
first result was ‘unclear’, ‘spoilt’, or a technical ‘failure’, and
they did not complete a subsequent kit. Screening uptake
was therefore computed using data on the outcomes of all
screening kits completed, and the denominator was the
number of invited subjects. We compared the effective-
ness of the ‘SI + Gist’ condition against ‘SI’ alone. The
primary outcome was the gradient in uptake rates over
quintiles of SES. Secondary outcomes were (i) overall
uptake; (ii) SES differences in uptake between the study
groups within age, gender, hub and screening round sub-
groups; (iii) time taken to return gFOBt; (iv) proportion of
spoilt kits; (v) screening result; and (vi) diagnostic out-
come for those with abnormal gFOBt results.
We used the Index of Multiple Deprivation (IMD)
2010 associated with each individual’s home address to
classify SES [22]. IMD is an area-based measure that
combines seven domains (e.g. income, employment, edu-
cation) into a single deprivation score. IMD scores were
grouped into quintiles from 1 (least deprived) to 5 (most
deprived). Data were available on age at invitation,
gender, hub, and screening round. The latter was cate-
gorised as incident screening (individual had previously
participated) and prevalent screening (individual had not
previously participated). The prevalent round of
screening was further divided into those who had not
previously been invited to screening (first time invitees)
and those who had previously declined screening (previ-
ous non-responders).
Statistical considerations
The target sample size was based on achieving a reduc-
tion in the SES gradient associated with screening up-
take. We assumed a fixed proportional effect in each
hub and estimated an average increase of 3 percentage
points, based on increasing uptake by 5 percentage
points in the lowest (fifth) IMD quintile (low SES) and 1
percentage point in the highest (first) quintile (high
SES), giving an overall 1–2–3-4-5 percentage point dif-
ference by quintile [23]. This is considered feasible
screening uptake research [24].
A published power calculation is available elsewhere
[25]. Briefly, with 90% power and 5% statistical signifi-
cance, 46,000 individuals (23,000 per arm) were required
to detect a 1–2–3-4-5 percentage point difference in
uptake in the least to most deprived IMD quintile, re-
spectively. However, due to the volume of invitations sent
out by each hub per week (70,000–80,000), this sample
would be achieved within 5 days. This number of clusters
would have a risk of bias [26]. The intervention therefore
ran for 10 days, providing a sample of 140,000–165,000.
The primary outcome was analysed by logistic regres-
sion in a univariable model, and then a multivariable
model adjusting for age, gender, hub and screening round.
P-values and 95% confidence intervals (CIs) were calcu-
lated using conservative variance estimation to allow for
potential clustering effects in randomisation [21, 26]. The
association between the proportion of people adequately
screened and SES was assessed by including an interaction
term for trial arm and IMD score (as a continuous vari-
able) in the models. The association was also investigated
by stratifying according to age at invite, gender, hub and
screening round. Analysis was performed on an intention-
to-treat basis using SAS v9.3 (SAS Institute Inc., Cary,
NC, USA) and Stata v12.1 (StataCorp LP, College Station,
TX, USA).
Availability of data and materials
The study data are available to the corresponding author
(CvW) and are not available for release as they contain
patient-identifiable information.
Assessment of concurrent initiatives
To determine whether the intervention was affected by
other initiatives, we surveyed national and local research
and health promotion activities during the trial. We sur-
veyed key informants, including Quality Assurance Ref-
erence Centre (QARC) Directors, a National Awareness
and Early Diagnosis Initiative (NAEDI) representative,
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Specialist Screening Practitioners (SSPs), BCSP
Programme Managers, the National Cancer Research
Network and Strategic Clinical Network representatives.
Results
Between the 5th and 16th of November 2012, 163,525
individuals were allocated to either the ‘SI’ intervention
(n = 79,104) or the ‘SI + Gist’ group (n = 84,421) based on
the hub-day (Fig. 1). Baseline characteristics were similar
in the groups (Table 1). Over half of all invitees
(n = 57.4%) were defined as adequately screened. Median
(range) time to return the kit was 22 days (11–142) for the
SI group and 23 days (12–142) for the SI + Gist group.
The proportion of spoilt test kits (n = 1256, 0.8%) or
undelivered mail (n = 822, 0.5%) was small and similar
across trial arms and IMD quintiles.
The proportion of adequately screened individuals
increased by 0.38 percentage points overall in the Gist
condition: SI + Gist = 57.6% versus SI = 57.3% (OR = 1.02,
95% CI: 0.92–1.13, p = 0.77). The proportion screened
decreased as deprivation score increased in both arms
(SI + Gist: 65.8% to 43.0% and SI: 65.6% to 42.0%), but
was similar between the trial groups in each IMD quintile,
providing no evidence that the intervention reduced
inequalities (interaction p-value = 0.48) (Table 2).
There was no difference in the proportion of individuals
adequately screened between the trial groups by age at
invitation (<65 years OR = 1.03, 95% CI: 0.94–1.13,
p = 0.52; 65–69 years OR = 0.98, 95% CI: 0.85–1.13,
p = 0.83; 70+ years OR = 1.04, 95% CI: 0.90–1.19,
p = 0.64). The proportion screened was generally lower in
younger individuals (<65 years 54.6% vs. 65–69 years
60.9% vs. 70+ years 57.3%), and decreased with deprivation
in both arms (Table 3). There was no evidence of an asso-
ciation between the trial arm and deprivation score on the
proportion screened in any age group (interaction p-value:
<65 years p = 0.86; 65–69 years p = 0.47; 70+ years
p = 0.46).
There was little difference in the overall proportion
adequately screened between the trial arms by gender
(men OR = 1.02, 95% CI: 0.92–1.14, p = 0.65; women
OR = 1.01, 95% CI: 0.91–1.12, p = 0.89). The proportion
screened was lower in men than women (55.7% vs. 59.1)
and decreased with deprivation in both arms (Table 4),
Allocated to SI group (n=79,104) Allocated to SI + Gist (n=84,421)
Randomised (n=163,525)
Analysable sample (n=79,104)
Missing IMD data (n=133)
Analysable sample (n=84,421)
Missing IMD data (n=138)
Fig. 1 Flow of participants through the trial
Table 1 Baseline characteristics
Variables SI + Gist
N = 84,421
SI
N = 79,104
median (range) median (range)
Age at invite (in years) 66.0 (59.0–74.0) 66.0 (59.0–74.0)
IMD deprivation score 14.9 (0.5–87.8) 14.8 (0.5–87.8)
% (n) % (n)
Gender
Female 51.2 (43195) 51.4 (40671)
Male 48.8 (41226) 48.6 (38433)
Socioeconomic status quintile
Least deprived (0–8.49) 22.6 (19055) 23.5 (18554)
2nd quintile (8.50–13.79) 23.5 (19787) 23.2 (18295)
3rd quintile (13.80–21.35) 21.7 (18320) 20.3 (15993)
4th quintile (21.36–34.17) 17.5 (14747) 17.1 (13469)
Most deprived (34.18–87.80) 14.7 (12374) 16.0 (12660)
Missing 138 133
Hub
Midlands & North West 26.6 (22469) 30.8 (24369)
Southern 24.5 (20651) 26.6 (21004)
London 8.8 (7416) 8.4 (6636)
North East 16.1 (13614) 16.3 (12858)
Eastern 24.0 (20271) 18.0 (14237)
Screening round
Incident episodes 53.3 (45019) 53.3 (42143)
Prevalent first time invitees 15.4 (13034) 15.7 (12410)
Prevalent previous non-responders 31.2 (26368) 31.0 (24551)
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but with no arm by deprivation interaction for men
(p = 0.33) or women (p = 0.78).
The proportion adequately screened was lower in
people who had not previously taken part in CRC
screening (prevalent first time invitees OR = 1.06, 95%
CI: 0.96–1.16, p = 0.23; prevalent previous non-
responders OR = 1.03, 95% CI: 0.94–1.13, p = 0.50; inci-
dent episodes OR = 1.01, 95% CI: 0.95–1.08, p = 0.67),
and decreased with deprivation in both arms (Table 5).
There was no difference in the overall proportion
screened between the trial arms according to previous
participation, nor an interaction with deprivation score
(interaction p-value: prevalent first time invitees
p = 0.13; prevalent previous non-responders p = 0.09;
incident episodes p = 0.38).
In the Southern Hub, overall uptake was lower in the
SI + Gist group (OR = 0.89, 95% CI: 0.84–0.94, p < 0.01)
and in each deprivation quintile, although there was no
effect after adjusting for baseline characteristics
(OR = 1.01, 95% CI: 0.95–1.07, p = 0.75). There was no
difference in uptake between trial arms in the other hubs
(Midlands & North West OR = 1.01, 95% CI: 0.83–1.24,
p = 0.89; London OR = 0.99, 95% CI: 0.64–1.52,
p = 0.96; North East OR = 1.03, 95% CI: 0.89–1.19,
p = 0.68; Eastern OR = 1.18, 95% CI: 0.97–1.43,
p = 0.09). An interaction with deprivation score was
seen in the London Hub (p < 0.01), but the proportion
screened was lower in the SI + Gist group than the SI
group among the most deprived individuals and the
reverse was seen in the least deprived group. This was
non-significant after adjusting for baseline characteristics
(p = 0.82). There was no interaction with deprivation
score in the Midlands & North West (p = 0.10), Southern
(p = 0.93), North East (p = 0.09), or Eastern (p = 0.58)
hubs (Table 6).
Of the 93,943 individuals adequately screened, 1703
(1.8%) had a definitive abnormal result. Diagnostic out-
comes are known for 1377 (80.9%) individuals with an
abnormal screening result (Additional file 3: Table S1).
We received details of 62 health promotion activities
and 17 research projects being undertaken during this
trial. These initiatives were not limited to occurring on
the same days the Gist leaflet was sent out.
Discussion
In this randomised controlled trial embedded within the
English NHS BCSP, a supplementary Gist leaflet contain-
ing essential and simple information about CRC screen-
ing combined with the standard information booklet did
not reduce SES inequalities in uptake compared with the
Table 2 Proportion of individuals who were adequately
screeneda, according to socioeconomic status quintileb
Variable SI + Gist*
N = 84,421
SI*
N = 79,104
% (n) % (n)
Adequately screened: 57.6 (48653) 57.3 (45290)
1st quintile (least deprived) 65.8 (12547) 65.6 (12178)
2nd quintile 62.2 (12305) 62.4 (11412)
3rd quintile 58.6 (10732) 58.4 (9335)
4th quintile 52.0 (7663) 51.9 (6987)
5th quintile (most deprived) 43.0 (5322) 42.0 (5316)
a Returned a gFOBt kit within 18 weeks of the invitation that led to a
‘definitive’ test result of either ‘normal’ (i.e. no further investigation required)
or ‘abnormal’ (i.e. requiring referral for further testing, usually colonoscopy) by
the date of data extraction (18 weeks after the last day of the intervention)
b 271 (138 SI + Gist and 133 SI) individuals missing socioeconomic status, 146
of these were adequately screened (84 SI + Gist and 62 SI)
*Comparison between trials groups: OR = 1.02, 95% CI: 0.92–1.13, p = 0.77
*Comparison between trials groups adjusting for age, gender, hub and
screening round: OR = 1.03, 95% CI: 0.99–1.06, p = 0.15
Table 3 Proportion of individuals who were adequately screeneda, according to socioeconomic status quintileb and median age at
invite
Age at invite <65 years* Age at invite 65–69 years* Age at invite 70+ years*
SI + Gist
N = 35,920
SI
N = 33,589
SI + Gist
N = 30,707
SI
N = 28,379
SI + Gist
N = 17,794
SI
N = 17,136
% (n) % (n) % (n) % (n) % (n) % (n)
Adequately screened: 54.9 (19727) 54.2 (18200) 60.8 (18657) 61.1 (17346) 57.7 (10269) 56.9 (9744)
1st quintile (least deprived) 63.6 (5135) 62.9 (4883) 69.1 (4740) 69.0 (4655) 64.9 (2672) 65.3 (2640)
2nd quintile 59.4 (4924) 59.0 (4449) 64.8 (4751) 66.5 (4476) 63.1 (2630) 61.9 (2487)
3rd quintile 54.9 (4201) 55.3 (3762) 61.8 (4224) 61.7 (3488) 60.1 (2307) 59.0 (2085)
4th quintile 50.0 (3206) 48.7 (2880) 55.3 (2961) 56.7 (2706) 50.3 (1496) 50.3 (1401)
5th quintile (most deprived) 41.0 (2226) 39.9 (2199) 45.5 (1946) 45.1 (1996) 43.1 (1150) 41.1 (1121)
aReturned a gFOBt kit within 18 weeks of the invitation that led to a ‘definitive’ test result of either ‘normal’ (i.e. no further investigation required) or ‘abnormal’
(i.e. requiring referral for further testing, usually colonoscopy) by the date of data extraction (18 weeks after the last day of the intervention)
b271 (138 intervention and 133 control) individuals missing socioeconomic status
*Comparison between trials groups within age at invite group: <65 years (OR = 1.03, 95% CI: 0.94–1.13, p = 0.52); 65–69 years (OR = 0.98, 95% CI: 0.85–1.13,
p = 0.83); 70+ years (OR = 1.04, 95% CI: 0.90–1.19, p = 0.64)
*Comparison between trials groups within age at invite group adjusting for gender, hub and screening round: <65 years (OR = 1.03, 95% CI: 0.99–1.07, p = 0.13);
65–69 years (OR = 1.00, 95% CI: 0.93–1.07, p = 0.93); 70+ years (OR = 1.06, 95% CI: 0.99–1.13, p = 0.08)
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existing materials alone. The Gist leaflet did not affect
overall uptake and there were no differences in the SES
gradient between the study groups within age, gender,
screening status or hub sub-groups. Screening uptake
was lower in the intervention arm of the Southern hub,
which generally serves more affluent areas. This effect
was removed in controlled analyses suggesting the indi-
vidual characteristics of each hub may not support a
‘one size fits all’ approach. The intervention was not af-
fected by concurrent initiatives.
Several studies have shown that people, particularly
older adults, have a preference for extracting gist-like
representations from health information, but this is
among the first attempts to evaluate information mate-
rials guided by Fuzzy-Trace Theory [27, 28]. Several
attempts have been made to increase screening uptake
using mailed materials informed by a range of
psychological theories, and these have resulted in posi-
tive, [29–31] negative [32] and null outcomes [33–35].
To our knowledge, no study has specifically attempted
to reduce the socioeconomic gradient in screening up-
take. This study was part of a programme of work evalu-
ating three other invitation strategies, a general practice
endorsement, an enhanced reminder and a narrative
leaflet describing people’s stories about screening [25].
Only the enhanced reminder affected the SES gradient
in uptake and marginal gains were observed in overall
uptake when using a general practice endorsement [36].
Despite the strong theoretical backgrounds and exten-
sive pre-testing of these interventions, the design of
effective strategies to promote colorectal screening
uptake is challenging.
Among the strengths of our trial were its national
coverage, substantial power to detect small differences
Table 4 Proportion of individuals who were adequately screeneda, according to socioeconomic status quintileb and gender
Males* Females*
SI + Gist
N = 41,226
SI
N = 38,433
SI + Gist
N = 43,195
SI
N = 40,671
% (n) % (n) % (n) % (n)
Adequately screened: 56.0 (23068) 55.4 (21273) 59.2 (25585) 59.1 (24017)
1st quintile (least deprived) 64.1 (5917) 64.3 (5762) 67.4 (6630) 66.9 (6416)
2nd quintile 60.6 (5863) 59.9 (5287) 63.7 (6442) 64.7 (6125)
3rd quintile 56.5 (5050) 56.5 (4385) 60.5 (5682) 60.1 (4950)
4th quintile 50.3 (3602) 49.8 (3274) 53.5 (4061) 53.8 (3713)
5th quintile (most deprived) 42.1 (2602) 40.6 (2535) 43.9 (2720) 43.4 (2781)
aReturned a gFOBt kit within 18 weeks of the invitation that led to a ‘definitive’ test result of either ‘normal’ (i.e. no further investigation required) or ‘abnormal’
(i.e. requiring referral for further testing, usually colonoscopy) by the date of data extraction (18 weeks after the last day of the intervention)
b 271 (138 SI + Gist and 133 SI) individuals missing socioeconomic status, 146 of these were adequately screened (84 SI + Gist and 62 SI)
*Comparison between trials groups within each gender: Males (OR = 1.02, 95% CI: 0.92–1.14, p = 0.65); Females (OR = 1.01, 95% CI: 0.91–1.12, p = 0.89)
*Comparison between trials groups within each gender adjusting for age, hub and screening round: Males (OR = 1.05, 95% CI: 1.01–1.10, p = 0.03); Females
(OR = 1.00, 95% CI: 0.96–1.05, p = 0.91)
Table 5 Proportion of individuals who were adequately screeneda, according to socioeconomic status quintileb and screening
round
Prevalent first time invitees* Prevalent previous non-responders* Incident episodes*
SI + Gist
N = 13,034
SI
N = 12,410
SI + Gist
N = 26,368
SI
N = 24,551
SI + Gist
N = 45,019
SI
N = 42,143
% (n) % (n) % (n) % (n) % (n) % (n)
Adequately screened: 49.6 (6466) 48.2 (5981) 14.5 (3836) 14.2 (3479) 85.2 (38351) 85.0 (35830)
1st quintile (least deprived) 58.3 (1708) 56.1 (1541) 16.9 (792) 17.8 (796) 87.9 (10047) 86.9 (9841)
2nd quintile 55.6 (1610) 53.4 (1473) 16.2 (898) 15.9 (790) 86.3 (9797) 86.6 (9149)
3rd quintile 49.7 (1352) 49.4 (1270) 15.5 (874) 15.3 (741) 85.4 (8506) 85.4 (7324)
4th quintile 43.7 (995) 42.3 (943) 13.0 (683) 12.7 (596) 83.1 (5985) 83.4 (5448)
5th quintile (most deprived) 36.0 (786) 35.9 (746) 11.2 (580) 10.0 (549) 79.2 (3956) 79.1 (4021)
aReturned a gFOBt kit within 18 weeks of the invitation that led to a ‘definitive’ test result of either ‘normal’ (i.e. no further investigation required) or ‘abnormal’
(i.e. requiring referral for further testing, usually colonoscopy) by the date of data extraction (18 weeks after the last day of the intervention)
b271 (138 intervention and 133 control) individuals missing socioeconomic status
*Comparison between trials groups within each screening round: Prevalent first time invitees (OR = 1.06, 95% CI: 0.96–1.16, p = 0.23); Prevalent previous non-
responders (OR = 1.03, 95% CI: 0.94–1.13, p = 0.50); Incident episodes (OR = 1.01, 95% CI: 0.95–1.08, p = 0.67)
*Comparison between trials groups within each screening round adjusting for age, gender and hub: Prevalent first time invitees (OR = 1.04, 95% CI: 0.98–1.10,
p = 0.17); Prevalent previous non-responders (OR = 1.03, 95% CI: 0.96–1.09, p = 0.44); Incident episodes (OR = 1.01, 95% CI: 0.96–1.07, p = 0.73)
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in uptake, and an intervention, which, if effective, could
easily and cost-effectively be incorporated into the existing
BCSP. We used novel, innovative methods to develop the
Gist leaflet, and carried out extensive user testing and
piloting to demonstrate its accessibility to adults with
basic literacy skills [17, 19]. A major limitation was that
we had to deliver the Gist leaflet as a supplement to, ra-
ther than a replacement for, the existing leaflet. Given that
complex written information is challenging for individuals
with limited literacy [37, 38], the effect of the Gist leaflet
may have been undermined by the increase in the volume
of material sent. Our findings should therefore not pre-
clude future studies evaluating the impact of a standalone
gist leaflet. We were also unable to record knowledge and
attitudes, and therefore the extent to which informed
decision-making was affected is unknown. Furthermore,
we did not attempt to address broader attitudes towards
cancer, such as cancer fatalism, which are known to affect
participation [6]. While low literacy may be an important
barrier to colorectal screening participation, it is possible
that other factors not addressed by the gist leaflet may be
more influential.
Conclusions
In conclusion, despite an extensive testing process our
supplementary information leaflet, giving the ‘gist’ of the
NHS BCSP in England neither increased overall uptake
nor reduced socioeconomic inequalities in screening.
Alternative strategies may be required to ensure groups
from lower socioeconomic status backgrounds, including
those with low levels of literacy, participate at similar
rates to their more affluent counterparts. The effective-
ness of the Gist leaflet when used alone is unknown and
should be investigated.
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